Published in Medicine (Baltimore) on September 01, 1968
Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet (1972) 2.99
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid (2015) 2.67
Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg (1980) 1.51
The early diagnosis of medullary carcinoma of the thyroid gland in patients with multiple endocrine neoplasia type II. Ann Surg (1975) 1.43
Parathyroid carcinoma in familial hyperparathyroidism. J Clin Pathol (1977) 1.08
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab (2013) 1.05
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol (2011) 1.05
Solid tumors associated with multiple endocrine neoplasias. Cancer Genet Cytogenet (2010) 1.04
Hyperparathyroidism: retrospect and prospect. Ann R Coll Surg Engl (1976) 1.03
Adenomas and carcinomas of the canine and feline thyroid. Am J Pathol (1976) 1.02
Immunochemical heterogeneity of calcitonin in plasma of patients with medullary thryoid carcinoma. J Clin Invest (1975) 1.00
Adrenal medullary hyperplasia. A morphometric analysis in patients with familial medullary thyroid carcinoma. Am J Pathol (1976) 0.98
The two-mutational-event theory in medullary thyroid cancer. Am J Hum Genet (1979) 0.95
Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer (2012) 0.94
Calcitonin and histaminase in C-cell hyperplasia and medullary thyroid carcinoma. A light microscopic and immunohistochemical study. Am J Pathol (1978) 0.92
Pheochromocytoma and paraganglioma. Prog Brain Res (2010) 0.91
The C cells (parafollicular cells) of the thyroid gland and medullary thyroid carcinoma. A review. Am J Pathol (1977) 0.89
Alterations in plasma norepinephrine concentration during surgical resection of pheochromocytoma. Ann Surg (1978) 0.89
Pheochromocytoma: present diagnosis and management. Ann Surg (1976) 0.88
Genetic factors in amyloidosis. J Med Genet (1975) 0.86
The parathyroid glands in multiple endocrine neoplasia type 2b. Am J Pathol (1980) 0.84
Advanced medullary thyroid cancer: pathophysiology and management. Cancer Manag Res (2013) 0.83
Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET. Pediatr Surg Int (2008) 0.83
Immunohistochemical study of pheochromocytomas. An investigation of methionine-enkephalin, vasoactive intestinal peptide, somatostatin, corticotropin, beta-endorphin, and calcitonin in 16 tumors. Am J Pathol (1984) 0.82
Sipple syndrome: marked variability of the disease within a family and implications for management. Postgrad Med J (1981) 0.82
Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer. Clin Med Insights Oncol (2011) 0.82
Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation. Fam Cancer (2009) 0.81
FNAC diagnosis of medullary carcinoma thyroid: A report of three cases with review of literature. J Cytol (2010) 0.81
Myotonic dystrophy and hyperparathyroidism: association with neurofibromatosis and multiple endocrine adenomatosis type 2A. J Neurol Neurosurg Psychiatry (1988) 0.81
Normal chromosomes in mucosol neuroma variant of medullary thyroid carcinoma syndrome. J Med Genet (1970) 0.81
Recent progress in calcium metabolism: clinical application. Calif Med (1971) 0.80
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J Oncol (2012) 0.80
Origins of ... familial cancer: histopathological perspectives. J Clin Pathol (1997) 0.80
My, How Things Have Changed in Multiple Endocrine Neoplasia Type 2A! J Clin Endocrinol Metab (2015) 0.79
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer. Onco Targets Ther (2011) 0.78
Multiple paragangliomata secreting catecholamines and calcitonin with intermittent hypercalcaemia. J R Soc Med (1979) 0.78
Multiple endocrine neoplasia type 2 (Sipple's syndrome): clinical and cytogenetic analysis of a kindred. J Med Genet (1984) 0.78
Integrated DNA-based/biochemical screening for early diagnosis of multiple endocrine neoplasia type 2A (MEN2A). J Biomed Res (2013) 0.78
The pathophysiology and clinical aspects of hypercalcemic disorders. West J Med (1978) 0.78
Medullary carcinoma of the thyroid gland. Ulster Med J (1980) 0.77
Hypertension secondary to pheochromocytoma. Bull N Y Acad Med (1982) 0.77
Multiple Endocrine Neoplasia: Genetics and Clinical Management. Surg Oncol Clin N Am (2015) 0.77
Controversies in familial thyroid cancer 2014. Ulus Cerrahi Derg (2014) 0.76
Cushing Disease in a patient with Multiple Endocrine Neoplasia type 2B. J Clin Transl Endocrinol Case Rep (2017) 0.75
The role of surgery in the management of thyroid cancer. Can Med Assoc J (1975) 0.75
Medullary carcinoma of the thyroid with parathyroid adenoma and hypercalcaemia. J Clin Pathol (1971) 0.75
An introduction to managing medullary thyroid cancer. Hered Cancer Clin Pract (2006) 0.75
Mucosal neuromata syndrome (MEN type IIb (III)). J Med Genet (1988) 0.75
Zollinger-Ellison syndrome and hyperparathyroidism. Proc R Soc Med (1971) 0.75
What is in a name: Is it Nelson's syndrome? Indian J Endocrinol Metab (2012) 0.75
Genetic analysis and clinical investigation of a pedigree with multiple endocrine neoplasia type 2A: A case report. Oncol Lett (2016) 0.75
Medullary carcinoma of thyroid gland in a girl aged 10 years. Arch Dis Child (1976) 0.75
Editorial: Familial medullary carcinoma of the thyroid. Br Med J (1974) 0.75
Tumor associated antigens. West J Med (1975) 0.75
Not just skin deep: a case report of multiple endocrine neoplasia type 1. Indian J Dermatol (2012) 0.75
Immunologic abnormalities in a patient with multiple neoplasms. Can Med Assoc J (1976) 0.75
Catecholamines--a symposium. Calif Med (1972) 0.75
Eye manifestations in medullary carcinoma of the thyroid. Br J Ophthalmol (1980) 0.75
Multiple endocrine neoplasia syndromes. West J Med (1980) 0.75
Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem (1972) 8.24
Radioimmunoassay for the measurement of adenosine 3',5'-cyclic phosphate. Proc Natl Acad Sci U S A (1969) 7.81
Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology (1997) 3.68
Human lymphocytic metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin. J Clin Invest (1971) 3.01
Radioimmunoassay for cyclic nucleotides. II. Adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in mammalian tissues and body fluids. J Biol Chem (1972) 2.84
Renal gluconeogenesis in acidosis, alkalosis, and potassium deficiency: its possible role in regulation of renal ammonia production. J Clin Invest (1966) 2.64
Cyclic adenosine 3',5'-monophosphate in human lymphocytes. Alterations after phytohemagglutinin stimulation. J Clin Invest (1971) 2.61
Effect of molybdenum starvation and tungsten on the synthesis of nitrogenase components in Klebsiella pneumonia. J Bacteriol (1974) 2.57
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler (2010) 2.30
Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology (1995) 2.07
Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest (1985) 2.00
Quantitative functional measures in MS: what is a reliable change? Neurology (2002) 1.81
The effect of oxotremorine and atropine on cGMP and cAMP levels in mouse cerebral cortex and cerebellum. Biochem Biophys Res Commun (1970) 1.72
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology (2007) 1.62
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology (2002) 1.61
Physiologic consequences of positive end-expiratory pressure (PEEP) ventilation. Ann Surg (1973) 1.58
Acid-base alterations and renal gluconeogenesis: effect of pH, bicarbonate concentration, and PCO2. J Clin Invest (1967) 1.55
Opsonic alpha2 surface binding glycoprotein therapy during sepsis. Ann Surg (1978) 1.49
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol (2001) 1.35
Radioimmunoassay for the measurement of cyclic nucleotides. Adv Cyclic Nucleotide Res (1972) 1.29
Hypernatremia due to hypodipsia and elevated threshold for vasopressin release. Effects of treatment with hydrochlorothiazide, chlorpropamide and tolbutamide. N Engl J Med (1968) 1.26
Cardiac output and pulmonary wedge pressure. Use for evaluation of fluid replacement in trauma patients. Arch Surg (1977) 1.25
Relation of renal cortical gluconeogenesis, glutamate content, and production of ammonia. J Clin Invest (1970) 1.24
Elevation of plasma glutamate in gout. Its possible role in the pathogenesis of hyperuricemia. N Engl J Med (1969) 1.21
A reappraisal of the in situ saphenous vein arterial bypass: its use in limb salvage. Surgery (1979) 1.19
Immunofluorescent localization of cyclic nucleotide-dependent protein kinases on the mitotic apparatus of cultured cells. J Cell Biol (1980) 1.19
Cyclic nucleotide immunocytochemistry. Adv Cyclic Nucleotide Res (1976) 1.17
Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler (2003) 1.16
Studies of pulmonary insufficiency in non-thoracic trauma. J Trauma (1972) 1.13
Effect of metabolic acidosis on renal gluconeogenesis in vivo. Am J Physiol (1968) 1.13
A method for detecting intracellular cyclic adenosine monophosphate by immunofluorescence. J Histochem Cytochem (1972) 1.12
The measurement of ambulatory impairment in multiple sclerosis. Neurology (1997) 1.11
"Blue toe" syndrome. An indication for limb salvage surgery. Arch Surg (1976) 1.11
Correlation of pulmonary wedge and left atrial pressures. A study in the patient receiving positive end expiratory pressure ventilation. Arch Surg (1974) 1.11
Rapid disease course in African Americans with multiple sclerosis. Neurology (2010) 1.10
Muscarinic cholinergic regulation of cyclic guanosine 3,5-monophosphate in autonomic ganglia: possible role in synaptic transmission. J Pharmacol Exp Ther (1975) 1.10
Cardiovascular hemodynamics after opsonic alpha-2-surface binding glycoprotein therapy in injured patients. Surgery (1979) 1.08
Quantitative assessment of motor fatigue and strength in MS. Neurology (1999) 1.08
Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. J Clin Invest (1974) 1.07
Localization of calmodulin in rat tissues. Proc Natl Acad Sci U S A (1980) 1.07
Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol (1999) 1.06
Arterial oxygen tension: significance in the surgical patient. Surgery (1972) 1.02
Effect of adenosine 3',5'-monophosphate on production of glucose and ammonia by renal cortex. J Clin Invest (1969) 1.02
Assay of cyclic nucleotides by radioimmunoassay methods. Methods Enzymol (1974) 1.02
Neurotransmitters increase cyclic nucleotides in postganglionic neurons: immunocytochemical demonstration. Science (1975) 1.01
Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol (1996) 1.00
Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol (2001) 0.99
Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology (2000) 0.99
Suppression and stimulation of calcitonin secretion in medullary thyroid carcinoma. Metabolism (1971) 0.99
Eikenella corrodens isolated in oral infections of dental origin. Oral Surg Oral Med Oral Pathol (1977) 0.99
Hypothalamic stimulation of growth hormone and thyrotropin lease in vitro and pituitary 3'5'-adenosine cyclic monophosphate. Endocrinology (1970) 0.98
Existence of two forms of immunoreactive growth hormone in human plasma. J Clin Endocrinol Metab (1972) 0.97
Sources of cyclic nucleotides in plasma. J Clin Invest (1974) 0.97
Compartmentalization of cyclic nucleotide-mediated hormone action. Annu Rev Pharmacol Toxicol (1978) 0.97
Detrimental effects of removing end-expiratory pressure prior to endotracheal extubation. Ann Surg (1980) 0.97
Clinical significance of the functional residual capacity in the post-injury state. Surg Forum (1971) 0.96
Disturbances in circulating opsonic activity in man after operative and blunt trauma. J Surg Res (1977) 0.96
The anatomy of inferior vena caval interruption. A technique for application of partial occlusion clip. Arch Surg (1968) 0.95
Temporal sequence of cell shape changes in cultured rat sertoli cells after experimental elevation of intracellular cAMP. Exp Cell Res (1981) 0.95
A new technique for removal of amorphous phase tissue water without ice crystal damage: a preparative method for ultrastructural analysis and immunoelectron microscopy. J Histochem Cytochem (1986) 0.94
Radioimmunoassay for cyclic nucleotides. 3. Effect of ischemia, changes during development and regional distribution of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in mouse brain. J Biol Chem (1972) 0.94
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler (2010) 0.94
Compartmentalization of cyclic AMP during phagocytosis by human neutrophilic granulocytes. Science (1981) 0.93
Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy. J Neurovirol (1999) 0.93
Conditioning of cyclophosphamide-induced leukopenia in humans. J Neuropsychiatry Clin Neurosci (1996) 0.93
The involvement of cyclic AMP in the hormonal regulation of protein synthesis in rat adipocytes. Endocrinology (1972) 0.93
Alterations in the intracellular distribution of cGMP and guanylate cyclase activity during rat liver regeneration. J Biol Chem (1978) 0.92
Correlation of positive end-expiratory pressure with cardiovascular performance. Crit Care Med (1975) 0.92
Increased oxygen consumption accompanying increased oxygen delivery with hypertonic mannitol in adult respiratory distress syndrome. Surgery (1978) 0.92
Cyclic nucleotides in pancreatic islets. Tolbutamide- and arginine-induced insulin release. Diabetes (1976) 0.92
Cardiopulmonary adjustments following single high dosage administration of methylprednisolone in traumatized man. Ann Surg (1975) 0.91
The measurement of cyclic nucleotides by radioimmunoassay. Adv Biochem Psychopharmacol (1970) 0.91
Lymphocyte surface modulation and cyclic nucleotides I. Topographic correlation of cyclic adenosine 3':5'-monophosphate and immunoglobulin immunofluorescence during lymphocyte capping. J Exp Med (1977) 0.90
Cyclic AMP and cyclic GMP: studies utilizing immunohistochemical techniques for the localization of the nucleotides in tissue. Metabolism (1975) 0.90
Localization of the catalytic subunit of cyclic AMP-dependent. Protein kinase in cultured cells using a specific antibody. J Cell Biol (1982) 0.90
Von Willebrand factor (VIII R:Ag), fibronectin, and insulin-like growth factors I and II in diabetic retinopathy and nephropathy. Diabetes (1984) 0.89
Capnocytophaga found in root canal system of a nonvital tooth. Oral Surg Oral Med Oral Pathol (1982) 0.89
Compartmentalization of cyclic nucleotides and cyclic AMP-dependent protein kinases in rat liver: immunocytochemical demonstration. Adv Cyclic Nucleotide Res (1978) 0.89
Pitfalls in the determination of plasma glutamate. N Engl J Med (1968) 0.89
Five-year experience with the Moretz vena caval clip in 62 patients. Arch Surg (1968) 0.89
Cyclic guanosine and adenosine 3',5'-monophosphates in canine thyroid: localization by immunofluorescence. Science (1974) 0.89
Continuous positive airway pressure in prophylaxis of adult respiratory distress syndrome in trauma patients. Surg Forum (1978) 0.88
Immunohistochemical localization of 3': 5'-cyclic AMP and 3': 5'-cyclic GMP in rat liver, intestine, and testis. Proc Natl Acad Sci U S A (1975) 0.88
Phosphorylation of chromosomal and ribosomal proteins and intracellular levels of cyclic 3',5'-adenosine monophosphate and cyclic 3',5'-guanosine monophosphate during amino acid starvation in Landschutz tumour cells. Exp Cell Res (1974) 0.87
Cyclic nucleotide and protein kinase immunocytochemistry. Adv Cyclic Nucleotide Res (1979) 0.87
Autonomic neuropathy associated with autoimmune disease. Neurology (1985) 0.87
Radioimmunoassay of the regulatory subunit of type I cAMP-dependent protein kinase. J Biol Chem (1979) 0.86
The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J Clin Virol (2000) 0.86
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler (2008) 0.86
Early effects of phytohemagglutinin (PHA) on lymphocyte cyclic AMP levels. Int Arch Allergy Appl Immunol (1971) 0.86
Immunocytochemical localization of cyclic GMP, cGMP-dependent protein kinase, calmodulin and calcineurin in Paramecium tetraurelia. Eur J Cell Biol (1983) 0.85
Detection of cardiac disturbances following thoracic trauma with high-frequency analysis of the electrocardiogram. J Trauma (1977) 0.85
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology (2009) 0.85
Compartmentation of second messenger action: immunocytochemical and biochemical evidence. Vitam Horm (1985) 0.85
Pathogenesis of Bartter's syndrome. N Engl J Med (1969) 0.85
Effects of a purified growth hormone releasing factor on growth hormone secretion and pituitary cyclic nucleotide content. Metabolism (1973) 0.84
Immunohistochemical localization of 3':5'-cyclic AMP and 3':5'-cyclic GMP in rat renal cortex: effect of parathyroid hormone. Proc Natl Acad Sci U S A (1977) 0.84
Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol (1997) 0.84
Regulation of hepatic nuclear guanylate cyclase. Proc Natl Acad Sci U S A (1977) 0.84